摘要
目的:分析复发性套细胞淋巴瘤患者联合使用沙利度胺与R-GEMOX方案的效果。方法:选取2019年6月至2021年6月福建医科大学附属南平第一医院收治的复发性套细胞淋巴瘤70例患者,比较单纯使用R-GEMOX方案(常规组)与沙利度胺联合R-GEMOX方案(观察组),两组患者近期疗效、远期疗效、不良反应发生率、生活质量。结果:观察组患者近期疗效与远期疗效均优于常规组患者,差异有统计学意义(P<0.05);观察组不良反应发生率5.71%低于常规组25.71%,差异有统计学意义(P<0.05);两组治疗前生活质量评分比较差异无统计学意义(t=0.30,P=0.764);治疗后两组生活质量评分均升高,观察组各项评分均高于常规组,差异有统计学意义(P<0.05)。结论:沙利度胺联合R-GEMOX方案治疗复发性套细胞淋巴瘤有着显著疗效,能提高患者生活质量及生存率,且能降低不良反应。
Objective:To analyze the effect of thalidomide combined with R-GEMOX regimen in patients with recurrent mantle cell lymphoma.Methods:A total of 70 patients with recurrent mantle cell lymphoma admitted to Nanping First Hospital Affiliated to Fujian Medical University from June 2019 to June 2021 were selected.The short-term efficacy,long-term efficacy,incidence of adverse reactions and quality of life of patients in the two groups were compared between R-GEMOX regimen alone(conventionl group)and thalidomide combined with R-GEMOX regimen(observation group).Results:The short-term and long-term efficacy of the observation group were better than those of the conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.71%lower than that in the conventional group 25.71%,and the difference was statistically significant(P<0.05).There was no significant difference in the quality of life score between the two groups before treatment(t=0.30,P=0.764).After treatment,the quality of life scores of the two groups were increased,and the scores of the observation group were higher than those of the conventional group,and the differences were statistically significant(P<0.05).Conclusion:Thalidomide combined with R-GEMOX regimen has a significant effect in the treatment of relapsed mantle cell lymphoma,which can improve the quality of life and survival rate of patients and reduce adverse reactions.
作者
高海枝
GAO Haizhi(Nanping First Hospital Affiliated to Fujian Medical University,Nanping Fujian 353000,China)
出处
《药品评价》
CAS
2022年第19期1180-1183,共4页
Drug Evaluation
